No Man

Sign in

Join Free
Post RFQ

Palbociclib

TypeName: Business Offer

Category:

Offer Date:2019/07/13

Country: United States

Summary: Palbociclib is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. https://www.bocsci.com/palbociclib-cas-571190-30-2-item-456204.html

Description:

OfferId: 4901

Name:Alex Brown

Telphone:

Email:[email protected]